Monoamine oxidase (MAO) [E.C. 1.4.3.4 .] is a flavin-containing enzyme that catalyzes the oxidative deamination of neurotransmitter amines as well as exogenous amines. [1] [2] [3] [4] It has been divided into two subtypes, MAO-A and MAO-B, on the basis of their different specificities toward substrates and inhibitors. [5] [6] [7] [8] [9] [10] Recently, determination of the sequence of cloned MAO-A and MAO-B cDNAs has provided the molecular basis for the existence of physically and genetically independent enzymes. 11, 12) Both forms appear to be important for neurotransmitter regulation, and fluctuations in functional MAO activity may be associated with human diseases such as Parkinson's disease, depression and certain psychiatric disorders. [13] [14] [15] [16] [17] In the human brain, MAO-B predominates (MAO-B : MAO-Aϭ4 : 1) and is associated mainly with glial cells. 18) Unlike most enzyme or neurotransmitter receptors and transporters, MAO-B activity increases with normal aging and in neurodegenerative disease in glial cells in response to age-related or disease-associated neuron loss and gliosis. 19, 20) Positron emission tomography (PET) and single photon emission computed tomography (SPECT) have been successfully employed for non-invasive studies of the biochemical transformation and physiological processes in the living human brain, utilizing organic molecules labeled with a positron emitter or a single photon emitter. For the direct and non-invasive mapping and functional studies of the MAO-B activity in the living brain, 11 C-labeled pargyline, 21) l-deprenyl, 22) 123 I-labeled benzamide derivatives [23] [24] [25] and 123 I-labeled pargyline 26) have been investigated as ligands for PET and SPECT. Recently, a new reversible and highly selective MAO-B inhibitor, 5-[4-(benzyloxy)phenyl]-3-(cyanoethyl)-1,3,4-oxadiazole-2(3H)one (MD-230254), was developed.
27) The 11 C-labeled MD-230254 has been investigated in living baboon brain with PET, and appears to be as a good candidate for in vivo MAO-B specific experiments. 28) Despite attractive features associated with PET techniques, PET studies are still limited, since they usually require on-site cyclotrons. On the other hand, SPECT studies are more commonly used in nuclear medicine clinics. We have explored the feasibility of a [
123 I]radioiodinated MAO-B inhibitor as an alternative to [
11 C]MD-230254 for functional MAO-B studies in the brain with SPECT. We report here the synthesis of a novel series of iodinated MD-230254 analogues amenable to radiolabeling with 123 I or 125 I. In vitro and in vivo studies on the inhibitory potency and selectivity toward MAO-B were also performed in order to evaluate it as a new ligand for in vivo MAO-B studies with SPECT.
Results and Discussion
Chemistry Iodinated derivatives of MD-230254 were synthesized by the reaction outlined in Chart 1, based on the published procedure for MD-230254. 27 ) examined under the same conditions. The selectivity of these inhibitors toward MAO-B were estimated from the ratio of the IC 50 value (MAO-A/MAO-B). These ratios of IC 50 value (MAO-A/MAO-B) were Ͼ50000 (5a), Ͼ28000 (5b) and Ͼ45000 (5d), respectively, indicating high selectivity toward MAO-B. However, 5c was found to be a relatively weak MAO-B inhibitor (IC 50 , 130 nM). Thus, the most potent compound 5a (namely 2-IBPO), among the iodinated MD-230254 derivatives tested in vitro, was chosen for further evaluations. Kinetic studies of MAO-B inhibition by 2-IBPO are shown as a Lineweaver-Burk plot in Fig. 1 and Fig. 2 . The inhibition mechanism of 2-IBPO indicated the same pattern as MD-230254 itself, with a change of Lineweaver-Burk plot from competitive (without preincubation with enzyme, Fig. 1 ) to "pseudo" noncompetitive patterns, with a parabolic secondary replot (with preincubation with the enzyme, Fig. 2) . 27) On the basis of these results, a two-step interaction between 2-IBPO and MAO-B can be assumed according to equilibrum, 27) where the substrate (E) and inhibitor (I) combine rapidly to form a reversible complex EI which is isomerized slowly into a tighter complex EI* (Chart 2). The inhibition constant (Ki) value and an overall inhibition constant (Ki*) value at equilibrium were calculated as 2.4 nM and 3.8 nM, respectively.
Radiolabeling The electrophilic iododestannylation reaction offers several advantages for radioiodination, since it is performed under very mild conditions and with very high regional selectivity, and also affords a high specific radioactivity. Thus, the preparation of 
using an iododestannylation reaction with a tributylstannyl precursor by the reaction outlined in Chart 3. The compound 5a was synthesized with hexa-n-butylditin in the presence of a catalytic amount of tetrakis-(triphenylphosphine)palladium to produce the corresponding tributylstannyl derivative 6 in moderate to high yield (57.7%). 
Experimental
Melting points were determined on a Yanagimoto micro-melting point apparatus and uncorrected. Infrared (IR) spectra were taken on a JASCO IR-700 spectrometer. Proton magnetic resonance ( 1 H-NMR) spectra were recorded on a Varian Gemini-200 (200 MHz) spectrometer, and the chemical shifts are reported in ppm downfield from an internal tetramethylsilane standard. High-resolution mass spectra were obtained on a Hitachi M-80 instrument. The HPLC system used includes a Waters M-600 pump, a LambadaMax 481 ultravaiolet detector, a Beckman 170 NaI radioactivity detector, and a Cosmosil 5C18-AR column (10ϫ250 mm, Nacalai Tesque). Radioactivity was measured using an Aloka ARC-300 NaI (Tl) gamma scintillation counter.
[ 125 I]NaI was purchased from Amersham Japan. All other chemicals used were of reagent grade and were purchased commercially. Wistar rats and male ddY mice were obtained from Japan SLC Co., Ltd. These animals were kept at least one week before the experiments. Animals chow and drinking water were allowed ad libitum. Animals were housed and experiments were performed according to guidelines stipulated by the Osaka University of Pharmaceutical Sciences Animal Care and Use Committee.
Substituted Ethyl 4-(Benzyloxy)benzoate (2a-d)
To a stirred and cooled suspension of sodium hydride (2.4 g, 0.10 mol) in dry DMF (20 ml) was added dropwise a solution of ethyl 4-hydroxybenzoate or its derivative (0.10 mol) in dry DMF (40 ml). The stirred mixture was allowed to stand for 30 min at room temperature. Then, a solution of benzyl bromide derivatives in dry DMF (10 ml) was added dropwise. The reaction mixture was stirred for 5 h. The solvent was evaporated and the crude ester was washed with 100 ml ice water and then filtered, dried, and recrystallized from EtOH. Assay of MAO Activity Rat liver was homogenized with 10 volumes of 0.25 M sucrose and 0.05 mM phosphate buffer (pH 7.4) under cooling. The homogenates were centrifuged at 1000 g for 10 min to remove cell debris. The protein content was measured by the biuret method.
31) The MAO activity was assayed radiochemically using 22 mmol) and hexa-n-butykditin (0.34 ml, 0.67 mmol) were dissolved in dry toluene (5 ml), and a catalytic amount of tetrakis(triphenylphosphine)palladium was added. The mixture was refluxed for 48 h under an argon atmosphere. After cooling, the reaction mixture was filtered through celite. The filtrate was concentrated in vacuo and the oily residue was purified by column chromatography on silica gel elution with chloroform-MeOH (40 : 1) affording 6.
Yield I ]2-IBPO) Aqueous hydrogen peroxide (10 ml, 30% w/v) was added to a mixture of 6 (10 ml, 1 mg/ml in ethanol), 0.1 M HCl (0.1 ml), and sodium [
125 I]iodide (10 ml, 7.4 MBq, specific activity 7.4 TBq/mmol) in a sealed vial. The reaction was allowed to proceed for 30 min at room temperature, after which it was terminated by the addition of sodium bisulfite (0.1 ml, 100 mg/ml in water). [ 125 I]2-IBPO was isolated by HPLC using water-methanol (2 : 8, v/v) as an eluent at a flow rate of 3.0 ml/min. The product fractions were collected and the solvent was removed in vacuo. The final product, [ 125 I]2-IBPO, was taken up in an isotonic saline solution and passed through a 0.22 mm filter. The radiochemical yield was 90-95%. The radiochemical purity and specific activity were higher than 99% and 7.4 TBq/mmol, respectively, as determined by HPLC.
In Vivo Tissue Biodistribution Studies in Mice Groups of four male ddY mice (20-25 g) were injected intravenously through a lateral tail vein with [ 125 I]2-IBPO in 0.1 ml of saline solution. At the desired time interval after administration, the animals were sacrificed. Samples of blood and organs of interest were excised and weighed. The radioactivity was measured using a well-type NaI(Tl) gamma scintillation counter. The results were expressed in terms of the percentage of the injected dose per gram of blood or organs.
Effect ]2-IBPO, these mice were killed by decapitation. Samples of blood and organs of interest were excised, weighed, and the radioactivity of these samples measured. These results were expressed as a percentage of the injected dose per gram of blood or organs compared with the non-treated control mice, referred to as 100%.
